Conclusion
Our study based on a large cohort of patients affected by major depressive disorder suggests that mirtazapine treatment may be associated with the increased risk of developing hypothyroxinemia. Further investigations are needed to clarify the clinical relevance of this association and its long-term impact on the treated patients.